20 mg/ml Dorzolamide
5 ml Ophthalmic Solution
S3 Reg. No. 45/15.4/1035
Carbonic Anhydrase Inhibitor
20 mg/ml Dorzolamide
5 ml Ophthalmic Solution
S3 Reg. No. 45/15.4/1035
Each ml of GLAUCOPRESS Ophthalmic Solution contains: dorzolamide hydrochloride equivalent to 20 mg dorzolamide base and 0,0075 % m/v benzalkonium chloride as preservative.
Other ingredients are: sodium citrate, hydroxyethyl-cellulose, mannitol, sodium
hydroxide and purified water.
A.15.4 Ophthalmic Preparations, other.
Dorzolamide hydrochloride is a carbonic anhydrase inhibitor formulated for topical ophthalmic use.
Carbonic anhydrase (CA) is an enzyme found in many tissues of the body including the eye. It catalyses the reversible reaction involving the hydration of carbon dioxide and the dehydration of carbonic acid. In humans, carbonic anhydrase exists as a number of isoenzymes, the most active being carbonic anhydrase II (CA-II) found primarily in red blood cells (RBCs) but also in other tissues. Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction i n sodium and fluid transport. The result is a reduction in intraocular pressure (IOP).
Topically applied beta-adrenergic blocking agents also reduce IOP by decreasing aqueous humor secretion but by a different mechanism of action. When dorzolamide is added to a topical beta-blocker, there is an additional reduction in IOP. This is consistent with the reported additive effects of beta-blockers and oral carbonic anhydrase inhibitors.
When topically applied, dorzolamide reaches the systemic circulation. Dorzolamide accumulates in red blood cells (RBCs) during chronic dosing as a result of selective binding to CA-II while low concentrations of free dorzolamide in the plasma is maintained. Dorzolamide forms a single N-desethyl metabolite that inhibits CA-II less potently than dorzolamide but also inhibits a less active isoenzyme (CA-I). The m etabolite also accumulates in red blood cells (RBCs) where it binds primarily to CA-I.
Dorzolamide binds moderately to plasma proteins (approximately 33 %).
Dorzolamide is primarily excreted unchanged in the urine, the metabolite is also excreted in urine. After dosing ends, dorzolamide washes out of red blood cells (RBCs) nonlinearly, resulting in a rapid decline of agent concentration initially, followed by a slower elimination phase with a half life of about 4 months.
When dorzolamide was given orally to simulate the maximum systemic exposure after long term topical ocular administration, steady state was reached within 13 weeks. At steady state, there is virtually no free dorzolamide or metabolite in plasma.
CA inhibition in red blood cells (RBCs) is less than that anticipated to be necessary for a pharmacological effect on renal function or respiration. Similar pharmacokinetic results were observed after chronic topical administration of dorzolamide. However, some elderly patients with mild to moderate renal impairment (estimated CrCl 30 – 60 ml/min) had higher metabolite concentrations in red blood cells (RBCs), but no meaningful differences in carbonic anhydrase inhibition and no clinically significant systemic side effects were directly attributable to this finding.
GLAUCOPRESS is indicated in the treatment of elevated intra-ocular pressure in
• ocular hypertension
• open angle glaucoma
• pseudoexfoliative glaucoma and other secondary open-angle glaucomas
•Hypersensitivity to dorzolamide or any of the ingredients contained in GLAUCOPRESS.
• GLAUCOPRESS has not been evaluated in patients with moderate to severe
renal impairment (i.e. creatinine clearance less than 30 ml/minute). Due to
renal excretion of dorzolamide and N-desethyldorzolamide, topical ocular use of
GLAUCOPRESS in patients with severe renal impairment is not recommended.
• GLAUCOPRESS has not been evaluated in patients with hepatic impairment, and
GLAUCOPRESS should be used with caution in such patients.
• GLAUCOPRESS has not been evaluated in patients wearing contact lenses. The
preservative in GLAUCOPRESS, benzalkonium chloride, may be absorbed by soft
GLAUCOPRESS is a sulphonamide and topical administration can result in systemic
absorption. Thus side-effects pertaining to sulphonamides may be experienced.
These include Stevens-Johnson Syndrome, toxic epidermal necrolysis, fulminant
hepatic necrosis, agranulocytosis, aplastic anaemia and other blood dyscrasis.
Sensitisation may recur when a sulphonamide is re-administered irrespective of
the route of administration.
If signs of serious reactions or hypersensitivity occur, discontinue the use of
GLAUCOPRESS and consult your doctor.
There is a potential for an additive effect on the systemic effects of the inhibition
of carbonic anhydrase in patients taking an oral carbonic anhydrase inhibitor and
GLAUCOPRESS concurrently. Thus concurrent administration of the GLAUCOPRESS
and oral carbonic anhydrase inhibitors is not recommended (See ‘’INTERACTIONS’’).
Safety and efficacy of dorzolamide ophthalmic solution in children younger than 16
years of age has not been established.
In patients 65 years of age or older compared with younger patients, safety and
efficacy of dorzolamide were similar however the possibility of greater sensitivity of
some older patients cannot be ruled out.
In clinical studies, local ocular adverse effects, primarily conjunctivitis and lid reactions,
were reported with chronic administration of GLAUCOPRESS ophthalmic solution.
Some of these reactions had the clinical appearance and course of an allergictype
reaction that resolved upon discontinuation of GLAUCOPRESS therapy. If such
reactions occur, treatment with GLAUCOPRESS should be discontinued, and the
patient evaluated before restarting GLAUCOPRESS is considered.
As the possibility of adverse effects on the corneal permeability, and the danger
of disruption of the corneal epithelium with prolonged or repeated usage of
benzalkonium chloride preserved ophthalmological preparations, cannot be
excluded, regular ophthalmological examination is required. Caution should
be exercised in the use of benzalkonium chloride preserved topical medication,
such as GLAUCOPRESS, over an extended period in patients with extensive ocular
The management of patients with acute angle-closure glaucoma requires
therapeutic intervention in addition to ocular hypotensive agents.
Incorrect handling of ophthalmic solutions can result in bacterial contamination of
the solution and subsequent ocular infections. Thus avoid allowing the tip of the
dispensing container to come in contact with the eye or surrounding areas.
Serious damage to the eye and subsequent loss of vision may result from using
contaminated ophthalmic solutions.
GLAUCOPRESS contains mannitol, which may have a mild laxative effect.
Administration of eye drops may cause transient blurring of vision.
Specific interaction studies with GLAUCOPRESS have not been performed however,
in clinical studies dorzolamide was used concomitantly with the following medicines
without evidence of adverse interactions: timolol ophthalmic solution, betaxolol
ophthalmic solution and systemic medication including ACE-Inhibitors, calcium
channel blockers, diuretics, non-steroidal anti-inflammatory drugs (NSAIDs) and
hormones (e.g. oestrogen, insulin, thyroxine).
GLAUCOPRESS is a carbonic anhydrase inhibitor and although administered
topically, is absorbed systemically.
Acid-base disturbances have been reported with oral carbonic anhydrase inhibitors
and have in some cases resulted in interactions (e.g. toxicity associated with highdose
salicylate therapy). Thus the potential for such interactions in patients using
GLAUCOPRESS should be considered.
When GLAUCOPRESS is used in conjunction with beta adrenergic blocking agents,
the intraocular pressure lowering effect may be additive.
Concomitant administration with oral carbonic anhydrase inhibitors is not
recommended due to the potential for an additive effect on the known systemic
effects of carbonic anhydrase inhibition.
There are no adequate and controlled studies in pregnant women, and
GLAUCOPRESS is not recommended during pregnancy.
In rabbits given maternotoxic doses associated with metabolic acidosis greater than
or equal to 2,5 mg/kg/day, malformation of the vertebral bodies were observed.
It is unknown whether dorzolamide is excreted into human milk. Due to the potential
for serious adverse reactions to dorzolamide in breastfed infants, a decision should
be made whether to discontinue breastfeeding the infant or the medicine, taking
into account the importance of GLAUCOPRESS to the women.
Benzalkonium chloride may be absorbed by soft contact lenses. Patients wearing
soft contact lenses should be instructed to wait at least 15 minutes after
instilling GLAUCOPRESS to insert soft contact lenses (See “WARNINGS AND
If more than one topical ophthalmic medication is
being used, the medicines should be administered at least ten minutes apart.
When used as monotherapy, the dose is one drop of GLAUCOPRESS in the affected
eye(s) three times a day.
When used as adjunctive therapy with an ophthalmic ß-adrenergic blocker, the
dose is one drop of GLAUCOPRESS in the affected eye(s) twice daily.
When substituting GLAUCOPRESS for another ophthalmic antiglaucoma agent,
discontinue the other agent after completing the proper dosing on one day, and
start the GLAUCOPRESS the next day.
Burning and stinging, blurred vision, eye itching, tearing, conjunctivitis, eyelid
inflammation, eyelid irritation.
Transient myopia, superficial punctuate keratitis, eye pain and redness.
General disorders and administrative site conditions:
Nervous system disorders:
Respiratory, thoracic and mediastinal disorders:
Bitter taste, nausea.
Fulminant hepatic necrosis.
Blood and the lymphatic system disorders:
Agranulocytosis, aplastic anaemia
Skin and subcutaneous tissue disorders:
Rash, Stevens-Johnson syndrome, toxic epidermal necrolysis.
Immune system disorder:
Renal and urinary disorders:
Limited data is available in regard to overdosage in humans. Overdosage of
GLAUCOPRESS can be expected to result in electrolyte imbalances, systemic
acidosis and possible central nervous system effects.
Serum electrolyte levels (particularly potassium) and blood pH levels should be
Treatment is supportive and symptomatic.
Sterile clear colourless or slightly yellowish, slightly viscous solution.
Sterile Opaque, white, low density polyethylene, 5 ml dropper bottle, with white low density polyethylene capillary plugs and blue polypropylene cap in cardboard carton.
Store at or below 30 °C. Protect from light. Discard the product after 30 days of
Keep well closed. For external use only.
KEEP OUT OF REACH OF CHILDREN.
Actor Pharma (Pty) Ltd
Unit 7, Royal Palm Business Estate
646 Washington Street, Halfway House, Midrand, 1685
27 November 2014